Saad Ashraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saad Ashraf has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Burhan
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
6 shared publications - Biruk Demisse Ayalew
St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia
5 shared publications - Hamza Irfan
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan
5 shared publications - Muhammad Shahmeer Ullah Shah
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Ahila Ali
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Ayesha Shaukat
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in BMC Neurology
Safety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis
- 19 October 2026
- Published by Springer Nature in BMC Neurology
Open AccessSafety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis
- Open Access
- 23 September 2026
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (3) , 12
Stone Clearance Rates Following Extracorporeal Shock Wave Lithotripsy: Comparative Efficacy in Lower Pole and Other Renal Locations: A Prospective Observational Study.
Introduction: Extracorporeal shock wave lithotripsy (ESWL) remains a widely used non-invasive treatment for renal calculi, yet stone clearance in lower pole stones has been debated due to anatomical and gravitational factors. Methods: A prospective observational study was conducted at the Sindh Institute of Urology and Transplantation (SIUT), Karachi, between June and December 2022. A total of 105 patients with solitary renal stones measuring 4–20 mm was included. Patients were categorized by stone location: lower pole (Group 1), mid pole (Group 2), pelvis (Group 3), and upper pole (Group 4). All underwent ESWL on a Storz Modulith SLX lithotripter under a standardized protocol, with a maximum of three sessions. Stone-free status was assessed radiologically three weeks after treatment. Statistical analyses included chi-square and t-tests, with significance at p < 0.05. Results: The mean age of participants was 41.45 ± 12.32 years; 55.2% were male. The mean stone size was 12.3 ± 3.3 mm. The overall stone-free rate was 86.7%. Clearance was achieved in 85.7% of lower pole stones (Group 1), 84.6% in mid pole (Group 2), 87.2% in pelvis (Group 3), and 90.9% in upper pole (Group 4), with no statistically significant differences among groups (p = 0.967). Complications were minimal and self‑limited. Conclusion: ESWL achieved high short-term stone clearance rates across different intrarenal stone locations, with comparable outcomes observed between lower pole and non-lower pole calculi in this cohort. Larger multicenter studies incorporating anatomical and radiological predictors with longer follow-up are needed to validate these findings and optimize patient selection.
- 23 September 2026
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (3) , 12
Open AccessStone Clearance Rates Following Extracorporeal Shock Wave Lithotripsy: Comparative Efficacy in Lower Pole and Other Renal Locations: A Prospective Observational Study.
Introduction: Extracorporeal shock wave lithotripsy (ESWL) remains a widely used non-invasive treatment for renal calculi, yet stone clearance in lower pole stones has been debated due to anatomical and gravitational factors. Methods: A prospective observational study was conducted at the Sindh Institute of Urology and Transplantation (SIUT), Karachi, between June and December 2022. A total of 105 patients with solitary renal stones measuring 4–20 mm was included. Patients were categorized by stone location: lower pole (Group 1), mid pole (Group 2), pelvis (Group 3), and upper pole (Group 4). All underwent ESWL on a Storz Modulith SLX lithotripter under a standardized protocol, with a maximum of three sessions. Stone-free status was assessed radiologically three weeks after treatment. Statistical analyses included chi-square and t-tests, with significance at p < 0.05. Results: The mean age of participants was 41.45 ± 12.32 years; 55.2% were male. The mean stone size was 12.3 ± 3.3 mm. The overall stone-free rate was 86.7%. Clearance was achieved in 85.7% of lower pole stones (Group 1), 84.6% in mid pole (Group 2), 87.2% in pelvis (Group 3), and 90.9% in upper pole (Group 4), with no statistically significant differences among groups (p = 0.967). Complications were minimal and self‑limited. Conclusion: ESWL achieved high short-term stone clearance rates across different intrarenal stone locations, with comparable outcomes observed between lower pole and non-lower pole calculi in this cohort. Larger multicenter studies incorporating anatomical and radiological predictors with longer follow-up are needed to validate these findings and optimize patient selection.
- Open Access
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Open AccessReduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- Open Access
- 9 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71576
Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Acute ischemic stroke (AIS) is a leading cause of mortality and long‐term disability worldwide. Despite advances in acute stroke management, many patients continue to experience substantial neurological disability and incomplete recovery. Minocycline, a tetracycline antibiotic with anti‐inflammatory and neuroprotective properties and good blood–brain barrier penetration, has been investigated as a potential adjunctive therapy in AIS. Methods: A systematic search of major databases was conducted identifying randomized controlled trials evaluating minocycline in patients with AIS. Outcomes included functional and neurological recovery assessed using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel index (BI), as well as mortality and vascular events. Pooled effect estimates were calculated using random‐effects meta‐analysis. Results: Seven RCTs comprising 2197 patients were included, with 1093 receiving minocycline and 1104 receiving placebo or standard care. Functional independence at 3 months (mRS 0–2) showed no significant difference between groups (RR 1.28, 95% CI 0.97–1.69; I 2 = 84.9%). Minocycline was associated with lower NIHSS scores (MD −2.45, 95% CI −4.32 to −0.59; I 2 = 88.6%) and higher BI scores (MD 12.52, 95% CI 6.28–18.76; I 2 = 47.0%). Mortality (RR 0.66, 95% CI 0.39–1.090 and stroke recurrence or MI showed no significant differences (RR 0.97, 95% CI 0.69–1.37). Conclusions: Although a consistent improvement in functional independence was not demonstrated, minocycline showed signals of benefit in selected neurological outcomes with a favorable safety profile. These findings support the need for adequately powered, multicenter randomized trials to clarify its therapeutic role.
- 9 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71576
Open AccessAdjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: Acute ischemic stroke (AIS) is a leading cause of mortality and long‐term disability worldwide. Despite advances in acute stroke management, many patients continue to experience substantial neurological disability and incomplete recovery. Minocycline, a tetracycline antibiotic with anti‐inflammatory and neuroprotective properties and good blood–brain barrier penetration, has been investigated as a potential adjunctive therapy in AIS. Methods: A systematic search of major databases was conducted identifying randomized controlled trials evaluating minocycline in patients with AIS. Outcomes included functional and neurological recovery assessed using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel index (BI), as well as mortality and vascular events. Pooled effect estimates were calculated using random‐effects meta‐analysis. Results: Seven RCTs comprising 2197 patients were included, with 1093 receiving minocycline and 1104 receiving placebo or standard care. Functional independence at 3 months (mRS 0–2) showed no significant difference between groups (RR 1.28, 95% CI 0.97–1.69; I 2 = 84.9%). Minocycline was associated with lower NIHSS scores (MD −2.45, 95% CI −4.32 to −0.59; I 2 = 88.6%) and higher BI scores (MD 12.52, 95% CI 6.28–18.76; I 2 = 47.0%). Mortality (RR 0.66, 95% CI 0.39–1.090 and stroke recurrence or MI showed no significant differences (RR 0.97, 95% CI 0.69–1.37). Conclusions: Although a consistent improvement in functional independence was not demonstrated, minocycline showed signals of benefit in selected neurological outcomes with a favorable safety profile. These findings support the need for adequately powered, multicenter randomized trials to clarify its therapeutic role.
- 6 July 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (5) , 355-363
Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis
Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.
- 6 July 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (5) , 355-363
Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis
Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.
- Open Access
- 12 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70238
Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T 2 DM : Insights From a Systematic Review and Meta‐Analysis
Background: Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analysis compared their glycaemic, cardiometabolic and safety outcomes when added to metformin. Methods: Following PRISMA guidelines, PubMed, Embase, Cochrane, Scopus and ClinicalTrials.gov were searched from inception to September 2025. Randomized trials and observational studies comparing empagliflozin + metformin versus sitagliptin + metformin in adults with T2DM were included. Primary outcomes were changes in HbA1c, body weight, fasting glucose, lipid profile and blood pressure. Safety outcomes included urinary tract infections, genital infections, gastrointestinal disturbances and rash. Risk of bias was assessed using RoB 2.0 and the Newcastle–Ottawa Scale. Random‐effects models were used for meta‐analyses, and meta‐regression explored the impact of empagliflozin dose. Results: Eleven studies met eligibility criteria. Empagliflozin produced greater reductions in HbA1c, body weight, fasting glucose and systolic blood pressure compared with sitagliptin. Lipid changes were modest and inconsistent. Rates of urinary infections, gastrointestinal symptoms and rash were comparable between groups, whereas genital infections were significantly higher with empagliflozin. Rare but serious adverse events associated with SGLT2 inhibitors, including Fournier's gangrene and lower limb amputations, were not reported in the included trials. Meta‐regression showed no meaningful dose–response relationship for glycaemic or weight outcomes. Conclusions: In patients with T2DM on metformin, empagliflozin offers superior glycaemic and cardiometabolic benefits compared with sitagliptin, with an increase in genital infections. Both therapies are well tolerated, supporting empagliflozin as an effective metabolic add‐on option. Trial Registration: PROSPERO ID: CRD420251152360
- 12 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70238
Open AccessGlycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T 2 DM : Insights From a Systematic Review and Meta‐Analysis
Background: Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analysis compared their glycaemic, cardiometabolic and safety outcomes when added to metformin. Methods: Following PRISMA guidelines, PubMed, Embase, Cochrane, Scopus and ClinicalTrials.gov were searched from inception to September 2025. Randomized trials and observational studies comparing empagliflozin + metformin versus sitagliptin + metformin in adults with T2DM were included. Primary outcomes were changes in HbA1c, body weight, fasting glucose, lipid profile and blood pressure. Safety outcomes included urinary tract infections, genital infections, gastrointestinal disturbances and rash. Risk of bias was assessed using RoB 2.0 and the Newcastle–Ottawa Scale. Random‐effects models were used for meta‐analyses, and meta‐regression explored the impact of empagliflozin dose. Results: Eleven studies met eligibility criteria. Empagliflozin produced greater reductions in HbA1c, body weight, fasting glucose and systolic blood pressure compared with sitagliptin. Lipid changes were modest and inconsistent. Rates of urinary infections, gastrointestinal symptoms and rash were comparable between groups, whereas genital infections were significantly higher with empagliflozin. Rare but serious adverse events associated with SGLT2 inhibitors, including Fournier's gangrene and lower limb amputations, were not reported in the included trials. Meta‐regression showed no meaningful dose–response relationship for glycaemic or weight outcomes. Conclusions: In patients with T2DM on metformin, empagliflozin offers superior glycaemic and cardiometabolic benefits compared with sitagliptin, with an increase in genital infections. Both therapies are well tolerated, supporting empagliflozin as an effective metabolic add‐on option. Trial Registration: PROSPERO ID: CRD420251152360
- 20 March 2026
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 40 (2) , 255-270
Efficacy and Safety of Anrikefon (HSK21542) for Postoperative Pain. A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Postoperative pain remains a nearly universal experience, affecting up to 80% of surgical patients globally (1). Poorly controlled acute pain can delay recovery and also contributes to persistent p...
- 20 March 2026
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 40 (2) , 255-270
Efficacy and Safety of Anrikefon (HSK21542) for Postoperative Pain. A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Postoperative pain remains a nearly universal experience, affecting up to 80% of surgical patients globally (1). Poorly controlled acute pain can delay recovery and also contributes to persistent p...
- Open Access
- 15 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (1)
A Rare Clinical Manifestation of Disseminated Tuberculosis: Case Report of Tuberculous Meningitis With Flaccid Paralysis
This case highlights a rare presentation of disseminated tuberculosis in a child, manifesting as tuberculous meningitis and flaccid paralysis due to spinal tuberculosis. Timely initiation of antitubercular therapy, corticosteroids, and ventriculoperitoneal shunt placement led to full recovery, emphasizing tuberculosis consideration in atypical neurological presentations in unvaccinated children with exposure.
- 15 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (1)
Open AccessA Rare Clinical Manifestation of Disseminated Tuberculosis: Case Report of Tuberculous Meningitis With Flaccid Paralysis
This case highlights a rare presentation of disseminated tuberculosis in a child, manifesting as tuberculous meningitis and flaccid paralysis due to spinal tuberculosis. Timely initiation of antitubercular therapy, corticosteroids, and ventriculoperitoneal shunt placement led to full recovery, emphasizing tuberculosis consideration in atypical neurological presentations in unvaccinated children with exposure.